
Please see detailed guidance assumptions on page 7 of our Q3 press release. Link: go.novartis.social/4zSX3Wa
✓An innovative medicines company working to reimagine medicine. See our community guidelines: go.novartis.social/4bqbjuA

Please see detailed guidance assumptions on page 7 of our Q3 press release. Link: go.novartis.social/4zSX3Wa

Novartis delivered solid sales growth and core margin expansion in Q3, as priority brands and launches more than offset generic erosion. We have raised our full-year 2026 guidance* for core operating income. Link to press release: novartis.social/6018aLrvy #NVSQ326

#NVSQ326 Novartis social media posts on Q3 2026 results contain forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information. #NVSQ326 Novartis social media posts on Q3 2026 contain non-IFRS measures. An explanation of non-IFRS measures is available on our website Novartis quarterly financial results | Novartis. $NVS $NOVN

On Tuesday, October 27, Novartis will announce its Q3 2026 results. Register to listen here: novartis.social/6019aIWpv #NovartisNews $NVS $NOVN #NVSQ326

*Please see detailed guidance assumptions on page 7 of our Q2 press release. Link: novartis.social/6013v4CD7

#Investors: Novartis delivered a solid second quarter, returning to sales growth driven by continued momentum from priority brands. We remain on track to deliver our full-year guidance and mid-term outlook.* Press release: novartis.social/6013v4CD7 Webcast: novartis.social/6014v4CDC #NVSQ226 $NVS $NOVN

#NVSQ226 Novartis social media posts on Q2 2026 results contain forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information. #NVSQ226 Novartis social media posts on Q2 2026 contain non-IFRS measures. An explanation of non-IFRS measures is available on our website Novartis quarterly financial results | Novartis. $NVS $NOVN

On Tuesday, July 21, Novartis will announce its Q2 2026 results. Register to listen here: novartis.social/6017v2Nsl #NovartisNews $NVS $NOVN #NVSQ226

#Investors: Novartis delivered strong growth in priority brands and recent launches during Q1 2026, while US generic erosion weighed on results as expected. We remain on track to deliver our full year guidance. Press release: go.novartis.social/4cCsrje IR Webcast: go.novartis.social/4cL7uBm #NVSQ126 $NVS $NOVN

#NVSQ126 Novartis social media posts on Q1 2026 results contain forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information. #NVSQ126 Novartis social media posts on Q1 2026 contain non-IFRS measures. An explanation of non-IFRS measures is available on our website Novartis quarterly financial results | Novartis. $NVS $NOVN

On Tuesday, April 28, Novartis will announce its Q1 2026 results. Register to listen here: novartis.social/6017vGJTc #NovartisNews $NVS $NOVN #NVSQ126

#Investors: Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025 Press release: go.novartis.social/3ZTwccA IR Webcast: go.novartis.social/4aaJF4D #NVSQ425

#NVSQ425 Novartis social media posts on Q4 and Full-Year 2025 results contain forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information. #NVSQ425 Novartis social media posts on Q4 and Full-Year 2025 contain non-IFRS measures. An explanation of non-IFRS measures is available on our website Novartis quarterly financial results | Novartis. $NVS $NOVN

On Wednesday, February 4 Novartis will announce its Q4 and Full-Year 2025 results. Register to listen here: go.novartis.social/45NqoVz #NovartisNews $NVS $NOVN #NVSQ425

Delighted to announce the extension of the @WHO–@Novartis memorandum of understanding, continuing the provision of free multidrug therapy for #leprosy treatment and expanding support to include funding for single-dose rifampicin for post-exposure prophylaxis. For 25 years, WHO and Novartis have partnered to interrupt the transmission and eliminate leprosy disease. In 2024, #Jordan became the first country verified and acknowledged by WHO for elimination of leprosy showing when science, equity and partnership are aligned, disease elimination becomes within reach. Thank you Novartis for your continued support and I look forward to further expand our collaboration to promote #HealthForAll. who.int/news/item/21-01-2026…

#News: Today marks a milestone in our $23 billion US expansion plan, as we announce the opening of a state-of-the-art radioligand therapy (RLT) manufacturing facility in Carlsbad, CA. 🔗 go.novartis.social/47LONem